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The Janus kinase (JAK)/signal transducer and acti-
vator of transcription (STAT) pathway is involved in
many cellular processes, including cell growth and
differentiation, immune functions and cancer. It is
activated by various cytokines, growth factors, and
protein tyrosine kinases (PTKs) and regulates the
transcription of many genes. Of the four JAK iso-
forms and seven STAT isoforms known, JAK2 and
STAT3 are highly expressed in the brain where they
are present in the postsynaptic density (PSD). Here,
we demonstrate a new neuronal function for the
JAK/STAT pathway. Using a variety of complemen-
tary approaches, we show that the JAK/STAT
pathway plays an essential role in the induction of
NMDA-receptor dependent long-term depression
(NMDAR-LTD) in the hippocampus. Therefore, in
addition to established roles in cytokine signaling,
the JAK/STAT pathway is involved in synaptic plas-
ticity in the brain.
INTRODUCTION
The Janus kinases (JAKs) are a family of non-receptor protein
tyrosine kinases (PTKs) that consists of four mammalian iso-
forms: JAK1, JAK2, JAK3, and TYK2. They are activated in
a variety of different ways. In the canonical pathway, two JAK
molecules bind to two receptors that have dimerized in re-
sponse to ligand binding and the juxtaposed JAKs trans and/or
autophosphorylate resulting in their activation (Yamaoka et al.,
2004). This mode of activation applies, for example, to cytokine
receptors, growth-hormone like receptors and the leptin374 Neuron 73, 374–390, January 26, 2012 ª2012 Elsevier Inc.receptor. Alternatively, JAKs may be activated following stimula-
tion of G protein-coupled receptors (GPCRs), PTKs such as
PYK2 (Frank et al., 2002) and/or via intracellular calcium
changes (Frank et al., 2002; Lee et al., 2010). Once activated,
JAKs phosphorylate and activate downstream targets. The
best established downstream effector of JAK is the signal trans-
ducer and activator of transcription (STAT) family. Seven STAT
isoforms, named STAT1 to STAT4, STAT5A, STAT5B, and
STAT6, have been identified. Once phosphorylated by JAK,
STATs dimerize and are translocated to the nucleus where
they regulate the expression of many genes (Aaronson and
Horvath, 2002; Levy and Darnell, 2002; Li, 2008).
The JAK/STAT pathway is involved in many physiological
processes including those governing cell survival, proliferation,
differentiation, development, and inflammation. There is in-
creasing evidence that this pathway also has neuronal specific
functions in the central nervous system (CNS). For example,
the JAK/STAT pathway is involved in leptin-induced neuropro-
tection and in the control of food intake (Bjørbaek and Kahn,
2004; Tups, 2009). This pathway has also been linked to
Alzheimer’s disease and memory (Chiba et al., 2009a; Chiba
et al., 2009b). In particular, it has been shown recently that
mice injected with the JAK inhibitor AG490 have spatial working
memory impairment (Chiba et al., 2009b).
The cellular and molecular mechanism by which the JAK/
STAT pathway is involved in neuronal function is unknown.
It has, however, been shown that JAK can regulate the expres-
sion or function of several neurotransmitter receptors, including
g-amino-butyric acid (GABA) (Lund et al., 2008), muscarinic
acetylcholine (Chiba et al., 2009b), N-methyl-D-aspartate
(NMDA) and a-amino-3-hydroxy-5-methyl-4-isoxazole pro-
pionic acid (AMPA) receptors (Mahmoud and Grover, 2006;
Orellana et al., 2005; Xu et al., 2008). To investigate how the
JAK/STAT pathway may function within the CNS we have inves-
tigated whether it has a role in synaptic plasticity, the family of
Neuron
Role of JAK/STAT in Synaptic Plasticityprocesses that are widely believed to underlie memory forma-
tion in the CNS.
The two major forms of long-lasting synaptic plasticity in the
mammalian brain—long-term potentiation (LTP) and long-term
depression (LTD)—are characterized by a long-lasting increase
or decrease in synaptic strength, respectively. The dominant
forms of both LTP and LTD are triggered by the synaptic activa-
tion of one class of glutamate receptor, the NMDA receptor, and
are expressed as alterations in synaptic transmission mediated
by another class of glutamate receptor, the AMPA receptor (Col-
lingridge et al., 2004; Collingridge et al., 2010). However, how the
transient activation of NMDARs leads to these processes is not
fully understood.
We find that pharmacological inhibition of JAK blocks the
induction of NMDAR-LTD at CA1 synapses in the hippocampus.
This effect is highly selective since the same treatment that
completely prevents the induction of NMDAR-LTD has no effect
on LTP, depotentiation or LTD induced by the activation of
metabotropic glutamate receptors (mGluRs). We find that the
JAK2 isoform is enriched at synapses and knockdown of JAK2
also blocks the induction of NMDAR-LTD. Furthermore, activa-
tion of NMDARs, either pharmacologically or by low-frequency
stimulation (LFS), causes a transient activation of JAK2. We
also present evidence that the effects of JAK2 in NMDAR-LTD
are mediated via STAT3. Thus, pharmacological inhibition or
knockdown of STAT3 also blocks the induction of NMDAR-
LTD. Furthermore, LFS causes activation and nuclear transloca-
tion of STAT3. However, we find that the nuclear translocation
of STAT3 is not required for NMDAR-LTD, suggesting that the
effect of STAT3 during NMDAR-LTD occurs in the cytoplasm.
In summary, we show that the JAK/STAT pathway has a key
role in synaptic plasticity.
RESULTS
The JAK Inhibitor AG490 Specifically Blocks
the Induction of NMDAR-LTD
We first investigated the role of JAK in synaptic transmission and
synaptic plasticity in the Schaffer collateral-commissural path-
way (Figure 1). For the initial set of experiments we used extra-
cellular recording in acutely prepared rat hippocampal slices
and stimulated two independent inputs onto the same popula-
tion of neurons. We decided to test the effects of the JAK
inhibitor AG490 (10 mM), since this inhibitor has been shown to
interfere with learning and memory (Chiba et al., 2009b). We
found that AG490 had no effect on baseline transmission
(100% ± 1% before and 101% ± 1% during AG490 application,
n = 13). Next we tested the effects of AG490 on NMDAR-LTP,
since this is the most widely studied cellular correlate of learning
and memory (Bliss and Collingridge, 1993). However, we found
no difference between the level of LTP induced in the control
input, in which AG490was applied immediately after the tetanus,
or in the input tetanized in the presence of AG490 (Figure 1A).
Thus, the level of LTP obtained 30 min following the tetanus,
expressed as a percentage of baseline, was 135% ± 4% and
145% ± 3% (n = 4), respectively. These values were similar to
the level of LTP induced in untreated inputs (140%± 3%of base-
line, n = 6; Figure 1C).Since more recent evidence has suggested that NMDAR-LTD
is also involved in some forms of learning and memory (see
Collingridge et al., 2010) we next tested AG490 on this form of
synaptic plasticity. In all experiments, AG490 completely pre-
vented the induction of NMDAR-LTD induced by low-frequency
stimulation (LFS; comprising of 900 stimuli delivered at 1 Hz),
though usually a short-term depression remained (Figure 1B).
In all cases, the block of NMDAR-LTD was fully reversible since
a second, identical period of LFS induced LTD that was similar to
that observed under control conditions. Thus, 60 min following
the first LFS, delivered in presence of AG490, the responses
were 99% ± 4% of baseline and 60 min following the second
LFS, delivered after washout of AG490, they were 74% ± 11%
of baseline (n = 6). In contrast to the dramatic effect on the induc-
tion of NMDAR-LTD, AG490 had no effect on the expression
phase of this process. Thus, LFS induced an LTD that was
71% ± 9% and 72% ± 9% of baseline (n = 6), before and
following the application of AG490, respectively. Since these
experiments were all performed using two inputs, the ability
of AG490 to selectively and reversibly block the induction
of NMDAR-LTD without affecting baseline transmission or the
expression of NMDAR-LTD were all internally controlled.
Next, we explored whether the effects of AG490 were specific
for de novo NMDAR-LTD or whether it blocked all forms of LTD.
To do this we investigated depotentiation, the reversal of a previ-
ously potentiated input. For these experiments we compared, in
the two inputs, the level of depotentiation before the application
and in the presence of AG490. Under both sets of conditions,
LFS reversed LTP to baseline conditions (Figure 1C). For ex-
ample, in the test input the synaptic response was 137% ± 3%
and 93% ± 3% of baseline (n = 6), before and following the LFS.
In conclusion, these experiments have shown that the JAK
inhibitor AG490 has a highly specific effect on the induction of
NMDAR-LTD.
Evidence for a Role of Postsynaptic JAK in NMDAR-LTD
To establish the locus of action of AG490 we made whole-cell
recordings and added the compound to the filling solution (Fig-
ure 2). In all neurons loaded with AG490 (10 mM) it was not
possible to induce NMDAR-LTD using a pairing protocol (300
pulses, 0.66 Hz, at 40 mV; Figure 2A), whereas in interleaved
control experiments NMDAR-LTD was readily induced (Fig-
ure 2G). Thus, the responses were 99% ± 2% (n = 6) and
63%±4% (n = 7) of baseline, measured at least 30min after pair-
ing, respectively. These experiments demonstrate that the likely
locus of AG490 inhibition is within the postsynaptic neuron.
However they do not establish beyond reasonable doubt that
the target is JAK since all kinase inhibitors have off-target effects
(Bain et al., 2003), due largely to the huge diversity of protein
kinases expressed in neurons. The best way to establish the
target is to apply a panel of different inhibitors, on the realistic
assumption that the off-target effects of the structurally distinct
compounds will vary (Peineau et al., 2009). We therefore used
three additional JAK inhibitors (CP690550 [1 mM], JAK inhibitor I
[0.1 mM], and WP1066 [10 mM]). We also included two src inhib-
itors (PP2 [10 or 20 mM] or SU6656 [10 mM]) in the study, given
that src family PTKs are expressed postsynaptically and regulate
neuronal function (Lu et al., 1998; Yu et al., 1997), includingNeuron 73, 374–390, January 26, 2012 ª2012 Elsevier Inc. 375
Figure 1. AG490 Blocks the Induction of NMDAR-LTD but Not LTP or Depotentiation
(A) Pooled data (n = 4) showing that AG490 (10 mM) has no effect on baseline transmission or LTP. The duration of the drug application is indicated by the open
rectangle and the timing of the LTP induction protocol is marked by an arrow.
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Role of JAK/STAT in Synaptic Plasticityinsulin-induced LTD (Ahmadian et al., 2004). Similar to the
effects of AG490, we found that the other three JAK inhibitors
all fully blocked the induction of NMDAR-LTD (101% ± 2%
of baseline, n = 5, Figure 2B; 99% ± 2% of baseline, n = 6,
Figure 2C; and 99% ± 2% of baseline, n = 4, Figure 2D; respec-
tively). In contrast, neither PP2 nor SU6656 affected the induc-
tion of NMDAR-LTD (64% ± 3% of baseline, n = 7, Figure 2E;
and 64%± 3%of baseline, n = 11, Figure 2F; respectively). Apart
from blocking the induction of NMDAR-LTD none of the inhibi-
tors affected baseline transmission or other measured pro-
perties. The results are summarized in Figure 2G and collec-
tively demonstrate that JAK is required for the induction of
NMDAR-LTD.
JAK2 Knockdown Blocks the Induction of NMDAR-LTD
The available JAK inhibitors do not effectively distinguish
between the JAK isoforms. Of the four JAK isoforms present
in the body (JAK1, JAK2, JAK3, and TYK2), JAK2 is the most
highly expressed in the brain and has been found in the post-
synaptic density (PSD) fraction (De-Fraja et al., 1998; Murata
et al., 2000). Therefore, to investigate the role of JAK2 in
NMDAR-LTD directly, we used constructs coding for two dif-
ferent shRNAs against rat JAK2 or a control shRNA, plus GFP
as a transfection marker. The JAK2 shRNAs could effectively
knockdown JAK2, as assessed biochemically (shRNA-1: to
32% ± 8% and shRNA-2 to 13% ± 5% of control, n = 5; Fig-
ure 3A) and with immunocytochemistry (Figure 3B). We then
transfected hippocampal organotypic slices with these con-
structs to assess their effects on basal synaptic transmission,
by comparing AMPAR and NMDAR-mediated EPSCs between
pairs of transfected and neighboring untransfected neurons,
48–72 hr after transfection. There was no difference under
any condition, showing that knocking down JAK2 has no effect
on basal synaptic transmission (Figures 3C–3E). In the next set
of experiments we investigated the effects of these constructs
on NMDAR-LTD. In all cells examined, NMDAR-LTD was
absent in neurons transfected with the JAK2 shRNA constructs
(shRNA-1: 88% ± 9% of baseline, n = 7, Figure 3F; shRNA-2:
94% ± 15%, n = 6, Figure 3G). In contrast, NMDAR-LTD was
observed in all neurons transfected with the control shRNA
(51% ± 5% of baseline, n = 8; Figure 3H), and this was similar
to that observed in non-transfected cells (Amici et al., 2009).
These experiments further substantiate the pharmacological re-
sults identifying a role of JAK in NMDAR-LTD and support the
idea that the JAK2 isoform is critically involved in this process.
JAK2 Is Present in Dendritic Spines and Is Regulated
during NMDAR-LTD
We investigated the distribution of JAK2 in cultured hippo-
campal neurons using confocal microscopy (Figure 4A). JAK2
showed a highly punctate distribution that decorated dendrites,
labeled with microtubule-associated protein 2 (MAP2, Figures(B) A single example (top) and pooled data (bottom) showing that AG490 has n
a reversible manner (n = 6). The NMDAR-LTD induction protocol, in this and subs
times indicated on the graph and are averages of 4 successive recordings. Calib
(C) Pooled data (n = 6) showing that AG490 has no effect on depotentiation.
In all experiments, two inputs were stimulated alternately and responses are ave4Aa–4Ac00). A high proportion of JAK2 immunostaining was colo-
calized with PSD-95 (45% ± 3% of PSD-95 positive puncta
colocalized with JAK2; 54% ± 3% of JAK2 positive puncta colo-
calized with PSD-95, Figures 4Ad–4Ae00). We also confirmed,
using differential centrifugation, that JAK2 is expressed in the
synaptosomal (LP1) fraction (Figure 4B).
If JAK2 is indeed the isoform involved in NMDAR-LTD then it
would be expected that its activity would be regulated during
the induction of the process. We therefore measured the level
of phosphorylation of Tyr 1007/1008, as an indicator of its activity
(Feng et al., 1997). In the initial experiments we applied NMDA
(20 mM, 3 min), a treatment that induces a chemical form of
NMDAR-LTD (Lee et al., 1998). We found that at the three initial
time points measured (0, 5, and 30 min after NMDA treatment)
the activity of JAK2 in hippocampal slices was significantly
increased (145% ± 10%, n = 10; 167% ± 13%, n = 18; 150% ±
18% compared to control, n = 7, respectively; Figures 4C
and 4D). However, the activation was transient since there was
no significant difference in the level of phosphorylation mea-
sured 60 or 120 min later. The activation of JAK was dependent
on the presence of Ca2+ and was specific for NMDARs, since
neither an mGluR agonist (DHPG) nor a muscarinic agonist
(carbachol) affected JAK2 phosphorylation (Figures 4C and
4D). Consistent with the lack of effect of DHPG on JAK2 phos-
phorylation, AG490 had no effect on DHPG-LTD (Figure 4E),
a form of LTD induced by the activation of mGluRs (Palmer
et al., 1997).
Since there are some differences in the mechanism of LTD
induced by bath perfusion of NMDA compared with the LTD
induced by synaptic activation of NMDARs (Morishita et al.,
2001), we also measured JAK2 phosphorylation in CA1 den-
drites following LFS (Figures 4F and 4G). Electrical stimulation
also resulted in an increase in JAK2 activity (158% ± 16%
compared to nonstimulated slices, n = 24; Figure 4G) and this
required the synaptic activation of NMDARs since the increase
in phosphorylation was absent in slices treated with AP5 during
the LFS (116% ± 14%, n = 10; Figures 4F and 4G). Treatment
with inhibitors for the Ser/Thr protein phosphatases PP1 and
PP2B also prevented activation of JAK2 during LFS (okadaic
acid [1 mM]: 103% ± 17%, n = 9; cyclosporine A [50–250 mM]:
112% ± 27%, n = 5; Figures 4F and 4G).
In summary, the finding that JAK2 is enriched at synapses,
colocalizes with PSD-95 and is activated during LTD in an
NMDAR, Ca2+ and PP1/PP2B dependent manner, suggests
that this isoform is involved in NMDAR-LTD.
STAT3 Is Required for the Induction of NMDAR-LTD
The next question wewished to address is what the downstream
effector of JAK2 is in NMDAR-LTD. JAK2 is known to signal via
the PI3K/Akt pathway and the ras/MAPK pathway (Lanning
and Carter-Su, 2006; Zhu et al., 2001). However, inhibitors
of these pathways do not affect NMDAR-LTD, under ouro effect on pre-established LTD but blocks the induction of NMDAR-LTD in
equent figures, is marked by a horizontal line. The traces were obtained at the
ration bars: 0.5 mV / 10 ms.
rages of four successive recordings.
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Figure 2. JAK Inhibitors Block NMDAR-LTD
(A–F) Representative EPSC traces (top) and pooled data (bottom) of whole-cell patch-clamp recordings illustrating the block of NMDAR-LTD by AG490 (10 mM,
n = 6; A), CP690550 (1 mM, n = 5; B), JAK inhibitor I (0.1 mM, n = 6; C), andWP1066 (10 mM, n = 4; D) and the lack of effect of PP2 (10–20 mM, n = 7; E) and SU6656
(10 mM, n = 11; F) on NMDAR-LTD. Calibration bars for all traces: 25 pA/50 ms.
(G) Histogram showing the amplitude of NMDAR-LTD, plotted as a percentage of baseline, for the four JAK inhibitors and the two src family PTK inhibitors. Black
bars show a significant difference compared to control NMDAR-LTD (with or without DMSO, as appropriate; n = 7 and 28, respectively), and the gray bars show
no difference with control.
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Role of JAK/STAT in Synaptic Plasticityexperimental conditions (Peineau et al., 2009). Another possi-
bility is via STATs. The JAK/STAT pathway is a major signaling
pathway involved in many nonneuronal processes where JAK
activation leads to phosphorylation of STATs, which results in
their activation and translocation to the nucleus. We focused
on STAT3, since this isoform is present in the hippocampus
and PSD (Cattaneo et al., 1999; De-Fraja et al., 1998; Murata
et al., 2000). Therefore, we tested the effects of two compounds
that inhibit the activation of STAT3: Stattic (50 mM) and STA-21
(30 mM). We found that both STAT3 inhibitors prevented the
induction of NMDAR-LTD (99% ± 2% of baseline, n = 4, Fig-
ure 5A; and 96% ± 4% of baseline, n = 7, Figure 5B; respec-
tively), with a similar time-course as the JAK inhibitors.
These data are consistent with a scheme in which, during
NMDAR-LTD, activation of JAK2 leads to activation of STAT3.
In which case, inhibition of STAT3 would not be expected to
affect the activation of JAK2 (Beales and Ogunwobi, 2009;
Schust et al., 2006). To test whether this was indeed the case,
we treated cultured hippocampal neurons with Stattic and found
that this completely prevented the activation of STAT3 without
affecting the activation of JAK2 in response to the stimulation
of NMDARs (Figure 5C). This treatment also reduced basal levels
of STAT3 activity suggesting that there is a degree of constitutive
activation of STAT3.
To substantiate the involvement of STAT3 in NMDAR-LTD, we
used two different shRNAs against STAT3, which efficiently
knocked down the target protein in hippocampal cultured
neurons as assessed with immunocytochemistry (Figure 5D).
As with JAK2 shRNAs, the knockdown of STAT3 had no effect
on basal synaptic transmission, as assessed by comparing
AMPAR and NMDAR-mediated EPSCs between pairs of trans-
fected and neighboring untransfected neurons, 48–72 hr after
transfection in organotypic slices (Figures 5E and 5F). However,
no NMDAR-LTD could be observed in the cells transfected with
the shRNAs (Figures 5G and 5H), whereas NMDAR-LTD was
reliably induced in interleaved experiments in neurons trans-
fected with control shRNA (Figure 3H). With both shRNAs
against STAT3 there was a small decrease in the synaptic
response following the LTD stimulus protocol but this was similar
for both the test and control inputs, and significantly smaller
than for control LTD. When all these data are considered
together it strongly suggests that STAT3 is the isoform involved
in NMDAR-LTD.
STAT3 Is Activated and Translocated to the Nucleus
during NMDAR-LTD
Since, when activated, STAT3 translocates to the nucleus, we
wanted to see if this activation and translocation also occurs
during NMDAR-LTD. In cultured hippocampal neurons under
control conditions, STAT3 immunoreactivity was fairly evenly
distributed throughout the neuron, including the nucleus (Fig-
ure 6A). NMDA treatment (20 mM, 10 min) resulted in nuclear
translocation and activation of STAT3 (Figure 6A). Maximal
nuclear accumulation was observed immediately following
NMDAR stimulation and the effect persisted for between 1 and
2 hr (Figures 6A and 6B). There was a corresponding activation
of nuclear STAT3, as assessed by the phosphorylation of
Tyr 705 (P-STAT3), which also lasted for between 1 and 2 hr(Figures 6A and 6B). Consistent with the activation of STAT3
being mediated by JAK2, treatment of cultures with AG490 pre-
vented both the translocation of STAT3 and activation of nuclear
STAT3 (Figure 6C).
To investigate whether STAT3 is also activated by LFS
in hippocampal slices, we analyzed the levels of STAT3 and
P-STAT3 in the CA1 region of hippocampal slices by western
blotting. For these experiments, wemicrodissected both stratum
radiatum, which is enriched in CA1 dendrites, and stratum pyra-
midale, which is correspondingly enriched in CA1 cell soma (Fig-
ure 6D). We prepared a nuclear fraction from the microdissected
cell soma preparation and examined the expression of P-STAT3
relative to total STAT3. LFS resulted in a pronounced activation
of nuclear STAT3 (199% ± 23%, n = 14, Figures 6D and 6F),
which was absent if LFS was delivered in the presence of AP5
(94% ± 8%, n = 10), okadaic acid (87% ± 17%, n = 5) or cyclo-
sporine A (136% ± 46%, n = 5; Figures 6E and 6F). Interestingly,
LFS also resulted in activation of dendritic STAT3 (135% ± 10%,
n = 14; Figures 6D and 6F) and this effect was also dependent on
the synaptic activation of NMDARs (110% ± 11% in presence of
AP5, n = 10; Figures 6E and 6F). These results are consistent with
the immunocytochemistry (Figures 6A and 6B) in cultured
neurons and extend themby showing the dependence of nuclear
STAT3 activation on the PP1/PP2B protein phosphatase cas-
cade. Significantly, these results show that the synaptic activa-
tion of NMDARs can lead to the activation of STAT3 in dendrites.
The Translocation of STAT3 to the Nucleus Is Not
Required for NMDAR-LTD
Once activated, cytoplasmic STATs are translocated to the
nucleus where they bind to DNA specific sequences within the
promoter region to control gene expression. There is evidence
that rapid transcription may be involved in LTD (Kauderer and
Kandel, 2000). Therefore, to investigate whether the rapid
effect of inhibition of STAT3 on NMDAR-LTD was due to interfer-
ence with gene transcription we performed a variety of different
experiments.
We first tested galiellalactone, a STAT3 inhibitor that blocks
STAT3 binding to DNA without affecting STAT3 activation. In
all neurons loaded with galiellalactone (50 mM) NMDAR-LTD
was readily induced (58% ± 8% of baseline, n = 5; Figure 7A).
To further explore whether nuclear signaling is required for
NMDAR-LTD, we used a nuclear export inhibitor (leptomycin B,
50 nM) and this also failed to inhibit NMDAR-LTD (57% ± 3%
of baseline, n = 6; Figure 7B). To investigate transcrip-
tion more generally, we tested the effects of actinomycin D
(25 mM). In field recordings we followed NMDAR-LTD for 3 hr
after induction and observed no difference between the level of
LTD in the control and test inputs (69% ± 3% and 71% ± 2%
of baseline, n = 4, respectively; Figure 7C). We also performed
experiments in slices from which the cell body region of the slice
had been completely removed. Once again, NMDAR-LTD that
lasted at least 3 hr could be readily observed (76%± 3%of base-
line, n = 5, Figure 7D). These data collectively suggest that
NMDAR-LTD can be readily induced and expressed for at least
3 hr, without the need for gene transcription and that the effects
of inhibition of STAT3 are independent of an action within the
nucleus. As a final test of this, we blocked transcription usingNeuron 73, 374–390, January 26, 2012 ª2012 Elsevier Inc. 379
Figure 3. JAK2 Knockdown Blocks the Induction of NMDAR-LTD
(A) The efficiency of two JAK2 shRNAs, compared to one control shRNA, was assessed in HEK cells cotransfected with a plasmid coding for JAK2. The values
shown are relative to the ratio JAK2/GAPDH obtained from the cells transfected with JAK2 only. *significantly reduced compared to untransfected cells or the
control shRNA.
(B) Images of cultured neurons transfected with a plasmid coding for GFP and the control or JAK2 shRNA, as indicated, and labeled with a JAK2 antibody (red).
Scale bars: 10 mm.
(C–E) AMPAR-mediated EPSCs (EPSCA) and NMDAR-mediated EPSCs (EPSCN) were recorded in cells transfected (Trans) with a JAK2 shRNA or the control
shRNA, as indicated, and nearby untransfected cells (Untrans). Peak amplitudes (EPSCA, at70 mV) or the amplitude measured 60 ms poststimulation (ESPCN,
at +40 mV) were plotted for each pair (black circles). Gray symbols represent mean ± SEM. Insets show representative traces, which are averages of three
successive records. Calibration bars for all traces shown: 40 pA/20 ms.
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of Stattic under these conditions. In all neurons tested, NMDAR-
LTD was readily induced in the presence of actinomycin D
(63% ± 3% of baseline, n = 5; Figure 7E) but was fully blocked
by the additional inclusion of Stattic (50 mM) in the patch solution
(98% ± 2% of baseline, n = 5; Figure 7E).
In summary, activation of STAT3, but not its binding to DNA, is
required for the induction and early expression of NMDAR-LTD.
DISCUSSION
In the present study, we have shown that the JAK/STAT pathway
is engaged by the synaptic activation of NMDARs and that it is
required for the induction of NMDAR-LTD. The involvement of
the JAK/STAT pathway is specific for this form of LTD since it
was not involved in either depotentiation or mGluR-LTD and is
also not involved in LTP. While we cannot exclude a role of the
JAK/STAT pathway in other forms of synaptic plasticity, for
example in other regions of the CNS or under different experi-
mental conditions, these findings further support the notion
that a set of distinct molecules are associated with the different
major forms of synaptic plasticity in the CNS (i.e., NMDAR-
dependent and NMDAR-independent LTP and LTD). A scheme
that summarizes our observations is presented in Figure 8.
Mechanisms Involved in NMDAR-LTD
NMDAR-LTD has been the subject of considerable recent
interest with the increasing realization that this process is
involved in learning and memory and various pathological
processes. However, the understanding of its molecular mecha-
nism is incomplete. The first step involves Ca2+ entry via
NMDARs (Cummings et al., 1996) andCa2+ release from intracel-
lular stores (Daw et al., 2002; Reyes and Stanton, 1996). This
intracellular calcium increase leads to the activation of several
Ca2+-dependent proteins, including calmodulin (Mulkey et al.,
1993), hippocalcin (Palmer et al., 2005), and protein interacting
with C-kinase 1 (PICK1) (Terashima et al., 2008) and to the acti-
vation of the caspase-3 signaling pathway throughmitochondrial
stimulation (Li et al., 2010). The multiple calcium sensors then
interact with several downstream effectors involved in AMPAR
trafficking, including ABP/GRIP (Chung et al., 2000), AP2 (Lee
et al., 2002; Palmer et al., 2005), the Arp2/3 complex (Nakamura
et al., 2011; Rocca et al., 2008), PSD-95 and AKAP (Bhatta-
charyya et al., 2009; Kim et al., 2007), Rab5a (Brown et al.,
2005), as well as RalBP1 (Han et al., 2009). These processes
are all dependent on, and regulated by, protein phosphorylation.
In this regard, there is strong evidence for the involvement
of a Ser/Thr protein phosphatase cascade involving protein
phosphatase 2B (calcineurin) and protein phosphatase 1
(Mulkey et al., 1993, 1994) and the dephosphorylation of
Ser845 of GluA1 (Lee et al., 1998). In addition, there is also
evidence for the involvement of the Ser/Thr kinase, glycogen
synthase kinase-3 b (GSK-3b) (Peineau et al., 2007, 2009) and(F–H) The NMDAR-LTD induction protocol failed to induce LTD of EPSCA in cells t
shRNA tested; F and G) while an input-specific LTD was consistently observed in
protocol is marked by a horizontal line. Insets show representative traces of the te
induction; each trace is an average of three successive EPSCs. Calibration barsinhibition of the activity of protein kinase M zeta (PKMz) (Hrabe-
tova and Sacktor, 1996). A role for tyrosine phosphorylation also
appears to be important (Ahmadian et al., 2004; Hayashi and Hu-
ganir, 2004) though the mechanism of its involvement is not yet
understood.
Clearly, a fuller understanding of NMDAR-LTD is important
given its relevance to both learning and memory and various
neurological diseases. However, before this can be achieved
the major signaling pathways involved need to be identified.
A Role for JAK2 in NMDAR-LTD
Our conclusion that a member of the Janus kinases, JAK2, is
involved in NMDAR-LTD is based on several lines of comple-
mentary evidence.
First, we identified a role of JAK pharmacologically. The extra-
cellular recording experiments showed that the role of JAK
is specific for the induction of this one form of synaptic plas-
ticity, since baseline transmission, pre-established NMDAR-
LTD, depotentiation, mGluR-LTD and LTP were all unaffected
by a concentration of a JAK inhibitor that fully prevented the
induction of NMDAR-LTD.
Second, by loading inhibitors into neurons via the patch
pipette we were able to demonstrate that the site of action was
likely to be postsynaptic, which is consistent with the known
locus of induction of NMDAR-LTD as well as with the postsyn-
aptic localization of both JAK2 and STAT3. In addition, we
compared a panel of different inhibitors (Figure 8), which is
important due to off-target effects of all kinases inhibitors (Bain
et al., 2003; Peineau et al., 2009). The likelihood of four structur-
ally distinct compounds all having the same off-target effect that
explains the block of NMDAR-LTD is remote indeed. Consistent
with the extracellular experiments, there was no effect on base-
line transmission, which would have been observed as an alter-
ation in EPSC amplitude upon obtaining the whole-cell re-
cording. No alterations in other neuronal properties were
observed. Collectively, therefore, these results demonstrate a
highly specific role for JAK in NMDAR-LTD.
Third, we found that knockdown of the JAK2 isoform also
resulted in abolition of NMDAR-LTD. Given JAKs are important
for cell survival we were concerned that these knockdown
experiments would not be feasible. However, we found that
it was possible to perform experiments within 48–72 hr of
transfection at a time when neurons were healthy and both AM-
PAR- and NMDAR-mediated synaptic transmission were unaf-
fected. The elimination of NMDAR-LTD was not a consequence
of transfection since the control shRNA had no effect on
NMDAR-LTD.
Fourth, we found that the JAK2 isoformwas heavily expressed
at synapses, thereby positioning the enzyme in the right location
to be involved in synaptic plasticity. We have focused on JAK2,
since this isoform is the most highly expressed in the CNS.
In particular, whereas JAK2 is expressed in the PSD, JAK1,
JAK3, and TYK2 have not been detected in this structure (Murataransfected with the shRNAs for JAK2 (n = 7 and 6 for the first and second JAK2
cells transfected with the control shRNA (n = 8; H). The NMDAR-LTD induction
st (black circle) and control (white circle) inputs, before and 25–30 min after LTD
: 50 pA/40 ms.
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Figure 4. JAK2 Is Present and Regulated at Synapses
(A) (a–c00) JAK2 immunoreactivity (green) forms clusters distributed in close apposition with the dendritic arborization of primary hippocampal neurons labeled
withMAP2 immunoreactivity (red). Note that a subset of JAK2-immunoreactive clusters are localized at sites of dendritic spine protrusions (arrows in c–c00). (d–e00)
Coimmunofluorescence experiments reveals that a subpopulation of JAK2-immunoreactive clusters (green) also expresses PSD-95 immunoreactivity (red)
(arrows in d–d00 and e–e00). Scale bars: 10 mm.
(B) Biochemical fractionation of hippocampal lysates (Total) shows the presence of JAK2 and the enrichment of PSD-95 in the synaptosomal fraction (LP1).
(C) Representative western blots showing JAK2 phosphorylation of Tyr 1007/1008 (P-JAK2, upper), the total amount of JAK2 (middle) and b-actin (lower), in rat
hippocampal slices without any treatment (control) or 0 (n = 10), 5 (n = 18), 30 (n = 7), 60 (n = 7), and 120min (n = 5) after NMDA treatment (20 mM, 3min); before and
after NMDA treatment without calcium (0 Ca); and after DHPG (100 mM, 10 min), and carbachol (CCh, 50 mM, 10 min) treatment.
(D) Graph summarizing the level of JAK2 phosphorylation in the different conditions shown in (C), relative to the corresponding control. A significant increase of
JAK2 phosphorylation (activation) is observed 0, 5, and 30 min after the NMDA treatment but under no other conditions.
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isoforms are also involved in NMDAR-LTD, a role of one or
more of these isoforms in other synaptic processes cannot be
discounted.
Lastly, we found that the activity of JAK2was increased during
NMDAR-LTD. Again, this effect was specifically related to the
synaptic activation of NMDARs and the entry of calcium. The
activation of JAK2 also depended on the phosphatases PP1
and PP2B, which are critically involved in NMDAR-LTD (Mulkey
et al., 1993). These data suggest that JAK2 is downstream of
the Ser/Thr protein phosphatase cascade, but further work will
be required to establish the full details of its activation pathway.
Proteins of potential interest in this respect are GSK3b, possibly
via inhibition of Src homology-2 domain-containing phospha-
tase (SHP) 2 (Kai et al., 2010; Tsai et al., 2009) and/or proline-
rich tyrosine kinase 2, PYK2, which has been found to be
involved in LTD (Hsin et al., 2010) and which, in nonneuronal
systems, has been shown to associate with and activate JAK
(Frank et al., 2002; Takaoka et al., 1999).
A Role for STAT3 in NMDAR-LTD
Having established a role for JAK2 in NMDAR-LTD we next
wished to identify its downstream effector in this process. We
discounted the class 1A PI3K and MAPK pathways since inhibi-
tion of these cascades does not affect NMDAR-LTD at these
synapses under the conditions of our experiments (Peineau
et al., 2009). Instead, we focused on the STATs since these are
well established targets of JAKs in a wide variety of homeostatic
functions. There are many STAT isoforms so we focused our
attention on STAT3, since this is a common partner of JAK2
and is also expressed at the PSD (Murata et al., 2000). Again,
we obtained complementary evidence for a role of STAT3 in
NMDAR-LTD.
First, we found that two structurally unrelated inhibitors of
STAT, with selectivity toward STAT3, were able to block
NMDAR-LTD (Figure 8). Surprisingly, NMDAR-LTD was blocked
fairly rapidly, with a time course similar to that seen with the
JAK2 inhibitors. We confirmed that Stattic was able to inhibit
the activation of STAT3 without affecting the activation of
JAK2, which is consistent with a specific action downstream
of JAK2.
Second, two different STAT3 shRNAs also blocked NMDAR-
LTD reinforcing the role of this isoform in NMDAR-LTD. Since
STAT3 is a transcription factor involved in cell survival, using
a knockdown approach to investigate its physiological role has
limitations. The experiments were performed 2–3 days after
transfection onCA1 cells that appeared healthy by visual inspec-
tion. We found that both AMPAR and NMDAR-mediated syn-
aptic transmission was unaffected by knockdown of STAT3.
However, the LFS induction protocol resulted in a small rundown
in synaptic transmission in both inputs. Further experiments will
be required to establish the origin of this effect. With respect to
NMDAR-LTD, however, there was no difference between the(E) Field recording experiments showing DHPG-induced LTD (100 mM, 10 min, wh
(F andG) After delivering LFS, the tissue surrounding the stimulated area was anal
when the slices were treated with AP5 (50 mM, 45min, n = 10), okadaic acid (OA, 1
to the corresponding control condition.control and test inputs. These data fully support the conclusions
from the pharmacological experiments that activation of STAT3
is required for NMDAR-LTD.
Third, we observed a translocation of STAT3 from the cyto-
plasm to the nucleus uponNMDAR stimulation in cultured hippo-
campal neurons. This effect was associated with an increase in
activity of nuclear STAT3, as assessed by its phosphorylation
status. The activation of nuclear STAT3 was dependent on
JAK2 activation and they both had a similar time course, which
suggests that the kinetics of the pathway is determined primarily
by the activation status of JAK2.
Fourth, we found that nuclear STAT3 was also activated by the
synaptic activation of NMDARs in hippocampal slices and, simi-
larly to JAK2, this effect also required PP1 and PP2B. STAT3
activation was, unsurprisingly, most prominent in the nucleus
but there was also a significant activation of cytoplasmic
STAT3 in the dendritic fraction. While this is not unexpected,
since STATs are phosphorylated in the cytoplasm before they
are translocated into the nucleus, it could enable STAT3 to
have an additional signaling function outside of the nucleus.
Finally, we established that STAT3 does not play a role in
NMDAR-LTD via its role in transcription, by using a variety of
different approaches (Figure 8). Thus, inhibiting the binding of
STAT3 to DNA, preventing nuclear export, blocking transcrip-
tion, and removing the cell body region of the slice, which
contains the vast majority of neuronal soma, were all unable
to block the induction of NMDAR-LTD. Our finding that
NMDAR-LTD is independent of transcription differs from a
previous report (Kauderer and Kandel, 2000) for reasons that
are unclear. Of course, we cannot discount a role of transcription
at times beyond the 3 hr that we have investigated here. Indeed,
a plausible role for the increase in nuclear STAT3 activity that
we have observed may be in the regulation of proteins that are
required for later phases of the NMDAR-LTD process.
Our findings strongly suggest that STAT3 has nonnuclear
actions that are required for NMDAR-LTD. Unfortunately, little
is known concerning the role of STATs on targets other than
DNA. Recent evidence has implicated the regulation of microtu-
bules in NMDAR-LTD (Kapitein et al., 2011). Interestingly, it has
been shown that STAT3 can directly interact with proteins asso-
ciated with microtubules, such as stathmin and SCG10-like
protein (SCLIP), and regulate their polymerization (Gao and
Bromberg, 2006; Ng et al., 2006, 2010). One possibility then is
that STAT3 could regulate the stabilization of microtubules,
amechanism that is believed to be rapid, dynamic and reversible
(Gao and Bromberg, 2006).
Clinical Implications
The role of JAKs in oncogenesis and pathologies of the immune
system make these kinases attractive potential therapeutic
targets. In particular, JAK2 mutations underlie the myeloprolifer-
ative disorders: polycythemia vera, essential thrombocytosis,
and primary myelofibrosis (Delhommeau et al., 2010). Sinceite circles, n = 6) is not modified by AG490 (10 mM, 40 min, black circles, n = 5).
yzed. LFS activates JAK2 in CA1 dendrites (n = 24) but no activation is observed
mM, 45min, n = 5) or cyclosporine A (CsA, 50–250 mM, 45min, n = 5) compared
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Figure 5. STAT3 Is Required for the Induction of NMDAR-LTD
(A and B) Representative EPSC traces (top) and pooled data (bottom) of whole-cell patch-clamp recording illustrating the block of NMDAR-LTD by the STAT3
inhibitors Stattic (50 mM, n = 4; A) and STA-21 (30 mM, n = 7; B). Calibration bars: 40 pA/50 ms.
(C) Western blot and bar graphs showing that Stattic (50 mM, 30 min) blocks the activation of STAT3 but not the activation of JAK2 after NMDA treatment (20 mM,
10 min) of cultured hippocampal neurons (n = 4).
(D) Two shRNAs against STAT3 and the control shRNA were tested in immunochemistry on neurons in culture transfected with a plasmid coding for GFP and the
shRNA. The neurons were then labeled with a STAT3 antibody (red).
(E and F) EPSCA and EPSCN (as in Figures 3C–3E) were recorded from neurons transfected with 2 different STAT3 shRNA and nearby non transfected neurons.
Calibration bars: 40 pA/20 ms.
(G and H) Representative traces and pooled data, presented as in Figures 3F–3H, showing that homosynaptic NMDAR-LTDwas not observed in cells transfected
with the first (G) and second (H) shRNA against STAT3 (n = 8 for both). The experiments with the control shRNA were interleaved (Figure 3H). Calibration bars:
50 pA/40 ms
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Figure 6. STAT3 Is Activated and Translocated to the Nucleus during NMDAR-LTD
(A) STAT3 and P-STAT3 (Tyr 705) immunoreactivity in the cytoplasm and nuclei of hippocampal neurons in culture. NMDA treatment (20 mM, 10 min) induces an
increase of both STAT3 and P-STAT3 immunoreactivity in neuronal nuclei, 0, 30, and 60 min after NMDA treatment. Scale bar: 10 mm.
(B) The graphs show that the nuclear/cytoplasmic STAT3 signal ratio and the P-STAT3 signal intensity are significantly increased at these times, compared with
control values.
(C) AG490 (10 mM) pretreatment prevents the NMDA-induced increase of nuclear STAT3 and P-STAT3 immunoreactivity.
(D) After delivering LFS, the stratum radiatum surrounding the stimulating electrodes (dendrites) or the stratum pyramidale (CA1 cells bodies) close to the
stimulated area were microdissected. The nuclei from the cell bodies were isolated by centrifugation. The blots of P-STAT3 and STAT3 show that the phos-
phorylation of STAT3 was increased in both compartments. Lamin and GAPDH were used as a blotting control for the nuclei and dendrites, respectively.
(E) The blots show that no activation of STAT3 is observed when the slices are treated with AP5 (50 mM, 45 min), okadaic acid and cyclosporin A (as in Figures 4F
and 4G) prior and during LFS.
(F) Graphs summarizing the data obtained in (D) (n = 14) and (E) (n = 10 for AP5 and n = 5 for okadaic acid and cyclosporin A).
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Figure 7. Translocation of STAT3 to the Nucleus Is Not Necessary for NMDAR-LTD
(A) Pooled data of EPSC amplitudes in whole-cell patch-clamp recording showing that NMDAR-LTD can be induced in presence of galiellalactone (50 mM; n = 5),
a STAT3 inhibitor which block its binding to DNA.
(B) NMDAR-LTD can also be induced in presence of leptomycin B (50 nM; n = 6), a blocker of nuclear translocation.
(C) Experiments performed with field-recording, as in Figure 1, show that actinomycin D (25 mM) does not block pre-established NMDAR-LTD or the induction of
NMDAR-LTD even 3 hr after induction (n = 4). Calibration bars: 0.5 mV/20 ms.
(D) Experiments performed with field-recording in slices where the cell bodies have been removed, as shown on the diagram, showing that the nucleus is not
required for the induction of NMDAR-LTD (n = 5). Calibration bars: 0.5 mV/40 ms.
(E) Stattic (50 mM) can still block the induction of NMDAR-LTD even in presence of actinomycin D (25 mM), a transcription inhibitor (n = 5 for both conditions).
Calibration bars: 25 pA / 40 ms.
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Figure 8. Schematic Representation of the Role of the JAK/STAT Pathway in NMDAR-LTD
Stimulation of NMDARs leads to activation of JAK2 (phosphorylation) via a pathway involving Ca2+, PP2B and PP1. Activated JAK2 leads to activation of STAT3,
which then translocates to the nucleus. STAT3 also has cytoplasmic actions, which are required for NMDAR-LTD. The 14 treatments in red all inhibit
NMDAR-LTD, whereas the 4 treatments in blue do not. IMP: importin; NPC: nuclear pore complex; EXP: exportin.
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Role of JAK/STAT in Synaptic PlasticityJAK2 is overactivated in these pathologies, a specific JAK inhib-
itor has potential utility in the treatment of these diseases and
several clinical trials for JAK2 inhibitors are underway (Quinta´s-
Cardama et al., 2011). However, the effect of available JAK2
inhibitors on the other JAK isoforms and the inhibition of the
central role JAKs play as downstream effectors of cytokine
receptors have beenmajor issues so far (Pesu et al., 2008; Wilks,2008). The JAK2 inhibitor AG490 has also been shown to affect
spatial learning and memory (Chiba et al., 2009b). It was sug-
gested that this impairment was due to the downregulation of
the enzyme choline acetyltransferase and to the desensitization
of the M1-type muscarinic acetylcholine receptor (Chiba et al.,
2009b). We now show that inhibiting JAK2 results in blockade
of a specific form of synaptic plasticity, NMDAR-LTD.Neuron 73, 374–390, January 26, 2012 ª2012 Elsevier Inc. 387
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A complete description of experimental procedures is available online in the
supplemental information.
Inhibitors and shRNA Plasmids
A complete list of the inhibitors used is available in the supplemental informa-
tion. Organotypic slices were transfected using biolistic transfection with
HuSH shRNA constructs in pGFP-V-RS vector (Origene Technologies,
Rockville, MD, USA). The sequences of the 29-mer shRNAs against rat JAK2
were GCCATCAGCAAACTAAAGAAGGCAGGAAA for the shRNA-1 and
CAGCCTGTTTACTCCAGATTATGAACTGC for the shRNA-2. The sequences
for the shRNAs against rat STAT3 were ACTGGATAACTTCATTAGCAGA
ATCTCAA for the shRNA-1 and TTCTTCACTAAGCCTCCGATTGGAACCTG
for the shRNA-2. The sequence of the control, noneffective, shRNA used
was GCACTACCAGAGCTAACTCAGATAGTACT.
Preparation of Slices
The experiments on acute slices were performed on 400 mm thick parasagittal
hippocampal slices obtained from juvenile (13- to 17-day-old) Wistar rats, as
described previously (Peineau et al., 2007). Hippocampal organotypic slices
were prepared from 8-day-old Wistar rats, as described previously (Bortolotto
et al., 2011; Jo et al., 2010). Procedures involving animals and their care were
conducted in conformity with the institutional guidelines that are in compliance
with national (UK animals (Scientific Procedures) Act 1986 and D.L.n.116,
G.U., Suppl. 40, 1992) and international laws and policies (EEC Council
Directive 86/609, OJ L 358, 1, 12 December 1987; Guide for the Care and
Use of Laboratory Animals, U.S. National Research Council, 1996).
Electrophysiology
In all electrophysiology experiments, the CA3 region was removed. Extra-
cellular and whole-cell experiments were performed as reported previously
(Peineau et al., 2007).
Whole-cell voltage-clamp recordings on organotypic slices were made from
transfected CA1 pyramidal cells at 6–11 days in vitro andwere performed blind
with respect to the transfected plasmid. Two stimulating electrodes (test and
control input) were placed in the Schaffer collateral-commissural pathway
and stimulated at 0.05 Hz to record AMPAR EPSCs (Vh =70mV). Tomeasure
NMDAR EPSCs, neurons were held at +40 mV and the EPSC amplitude was
measured 60 ms following the stimulus. NMDAR-LTD was induced using
a pairing protocol (1 Hz for 6 min, Vh = 40 mV). Access resistance was moni-
tored constantly and neurons were discarded if this varied by more than 20%
during the recording period. Data were stored and analyzed using the WinLTP
Program (Anderson andCollingridge, 2007) and are presented asmean ±SEM.
Biochemistry
For chemically induced LTD, whole hippocampal slices (without CA3) were
treated with either 20 mM NMDA for 3 min, 100 mM DHPG for 10 min or 50 mM
carbachol for 10 min. For LFS-induced LTD, hippocampal slices were stimu-
lated (900 stimulations at 1Hz)with twoelectrodesplaced in theSchaffer collat-
eral-commissural fibers. The stratum radiatum surrounding the stimulating
electrodes, enriched in CA1 dendrites, and the stratum pyramidale, enriched
inCA1cell bodies,were thenmicrodissectedwithin thenext 10minandwashed
in a cold buffer. The nuclei were isolated by centrifugation from the stratum
pyramidale portion. The samples were then lysed and western blotting was
performed. The antibodies used were: rabbit anti-phospho-JAK2 (Tyr 1007-
1008, 09-275, Millipore, Billerica, MA, 1:500), rabbit anti-JAK2 (3230, Cell
Signaling Technology, Danvers, MA, 1:500), mouse anti-phospho-STAT3
(Tyr 705, sc-8059, Santa Cruz Biotechnology, Santa Cruz, CA, 1:100), mouse
anti-STAT3 (sc-8019, Santa Cruz Biotechnology, 1:100), mouse anti-b-actin
(ab6276, Abcam, Cambridge, MA, 1:10,000), rabbit anti-GAPDH (2118, Cell
Signaling Technology, 1:10,000), rabbit anti-lamin (2032, Cell Signaling Tech-
nology, 1:200) and mouse or rabbit secondary antibodies (Millipore, 1:10,000).
Hippocampal Cell Cultures
For STAT3 translocation to the nucleus, hippocampi were dissected from
18-day-old embryo Sprague-Dawley rat brains. Mature cultured neurons388 Neuron 73, 374–390, January 26, 2012 ª2012 Elsevier Inc.(day in vitro; DIV12) were treated with 20 mM D-serine as control or 20 mM
D-serine + 20 mM NMDA for 10 min at 37C and fixed at different time after
the treatment. Some neurons were pretreated with 10 mM AG490 for 30 min
and fixed immediately after the NMDA treatment.
To test the efficiency of the shRNAs and for the experiments with the inhib-
itor Stattic, hippocampi were dissected and dissociated and cultured from
2-day-old Wistar rats.
Transfection of the cells with the shRNAs was performed at DIV 4–6 using
lipofectamine according to the manufacturer’s protocol and the cells were
fixed 2–3 days later.
Pharmacological treatment with D-Serine and NMDA was performed as
described above, at DIV 4–8, on cells incubated with either vehicle control
DMSO or Stattic (50 mM) for 20–30 min. Cells were then washed and lysed in
a standard lysis buffer.
Immunocytochemistry
Neurons were fixed with paraformaldehyde 4% or methanol and incubated in
a donkey serum blocking buffer before labeling themwith JAK2 (sc-278; Santa
Cruz Biotechnology; 1:50 or ab39636, Abcam; 1:200), MAP2 (ab11268;
Abcam; 1:1,000), PSD-95 (05-494; Upstate Biotechnology, Billerica, MA;
1:200), STAT3 (124H6; Cell Signaling Technology; 1:400), or phospho-
STAT3 (9131; Cell Signaling Technology; 1:100). The coverslips were then
mounted with Fluoromount for microscopic observations. See supplemental
experimental procedures for details.
HEK Cells and Transfection
HEK293 cells were transfected with a pcDNA3-rJAK2(FL)-HA plasmid and
the different shRNAs, using an Amaxa Nucleofector Kit V according to the
manufacturer’s instructions. The cells were lysed in a standard lysis buffer
72 hr after transfection, and the levels of JAK2 and GAPDH were analyzed
by western blot.
Statistics
Two-tailed paired or unpaired Student’s t tests or one-way ANOVA were
carried out as appropriate, with a significance level set at p < 0.05 (and indi-
cated in the figures by an asterisk).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and can be found with this article online at doi:10.1016/j.neuron.2011.11.024.
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